Fortrea Holdings Inc（FTRE）财务数据FTREFortrea Holdings Inc

Fortrea Holdings Inc (FTRE) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Clinical Services, accounting for 91.5% of total sales, equivalent to $709.70M. Another important revenue stream is Enabling Services. Understanding this composition is critical for investors evaluating how FTRE navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, Fortrea Holdings Inc maintains a gross margin of 17.63%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 1.58%, while the net margin is -2.80%. These profitability ratios, combined with a Return on Equity (ROE) of -15.30%, provide a clear picture of how effectively FTRE converts its operational activities into shareholder value.

In the context of the broader market, FTRE competes directly with industry leaders such as STGW and ANDE. With a market capitalization of $2.29B, it holds a leading position in the sector. When comparing efficiency, FTRE's gross margin of 17.63% stands against STGW's 28.65% and ANDE's 7.22%. Such benchmarking helps identify whether Fortrea Holdings Inc is trading at a premium or discount relative to its financial performance.

Fortrea's gross margin has improved to 17.63% in Q2 2026, up from 14.89% in Q1 2025, indicating better efficiency in operations. Despite negative net income figures, the company has raised its revenue guidance for the year to $2.73 billion, up from $2.65 billion, showing confidence in future growth.